Drug
Imlifidase clinical trials
Also written IdeS and HMED-IdeS.
- studies test it
- 17
- open now
- 2
- in phase 3
- 4
- first study started
- 2013
Keep track of what changes. Save the imlifidase studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 11
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 4
Hansa Biopharma AB (12) · Cedars-Sinai Medical Center (1) · Mårten Segelmark (1) · Genethon (1) · Sarepta Therapeutics, Inc. (1) · Fundacion Clinic per a la Recerca Biomédica (1)
Often tested with
Tested in the same studies.
GNT0003 (1)
Studies
Open first, then newest update. How each study uses imlifidase is read from its arms, and is right about nine times in ten.
Testing it · 17
- Imlifidase Prior to Kidney Transplant in Highly Sensitised ChildrenRecruitingPhase 2Hansa Biopharma ABNCT05753930Written as Imlifidase
- Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar SyndromeRecruitingPhase 2GenethonNCT06518005Written as Imlifidase
- A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient GroupActive, not recruitingPhase 3Hansa Biopharma ABNCT05937750Written as Imlifidase administered in the 20-HMedIdeS-19 (PAES) study
- Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference CohortsCompletedPhase 3Hansa Biopharma ABNCT05369975Written as Imlifidase
- Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney TxCompletedPhase 3Hansa Biopharma ABNCT04935177Written as Imlifidase
- A Study With Imlifidase in Anti-GBM DiseaseTerminatedPhase 3Hansa Biopharma ABNCT05679401Written as Imlifidase
- A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)TerminatedPhase 1Sarepta Therapeutics, Inc.NCT06241950Written as imlifidase
- A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to TransplantationTerminatedPhase 2Hansa Biopharma ABNCT05049850Written as Imlifidase
- A Study of Imlifidase in Patients With Guillain-Barré SyndromeCompletedPhase 2Hansa Biopharma ABNCT03943589Written as Imlifidase
- Imlifidase in Living Donor Renal Transplantation Highly Sensitized RecipientsWithdrawnPhase 2Fundacion Clinic per a la Recerca BiomédicaNCT06461546Written as Imlifidase
- An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant PatientsCompletedPhase 2Hansa Biopharma ABNCT03897205Written as Imlifidase
- Ides in Highly Sensitized (HS) Patients Awaiting Kidney TransplantationCompletedPhase 1/2Cedars-Sinai Medical CenterNCT02426684Written as IdeS® (Imlifidase)
- Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM DiseaseCompletedPhase 2Mårten SegelmarkNCT03157037Written as Imlifidase
- A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch TestCompletedPhase 2Hansa Biopharma ABNCT02790437Written as IdeS
- Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney TransplantationCompletedPhase 2Hansa Biopharma ABNCT02475551Written as IdeS
- Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney DiseaseCompletedPhase 2Hansa Biopharma ABNCT02224820Written as IdeS
- Safety Study on IdeS in Healthy VolounteersCompletedPhase 1Hansa Biopharma ABNCT01802697Written as IdeS
Codes
What other systems call imlifidase · ClinicalTrials.gg INT018170
- UNII (FDA) UVJ7NL8S2PIMLIFIDASEConfirmed FDA, Wikidata
- Wikidata Q97353944imlifidaseConfirmed FDA, Wikidata
- NCI Thesaurus C170061ImlifidaseOne source FDA
- DrugBank DB15258One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | UVJ7NL8S2P | IMLIFIDASE | Confirmed FDA, Wikidata |
| Wikidata | Q97353944 | imlifidase | Confirmed FDA, Wikidata |
| NCI Thesaurus | C170061 | Imlifidase | One source FDA |
| DrugBank | DB15258 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.